Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of 2 dosing
regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had
progressed following treatment with a nonsteroidal aromatase inhibitor (AI).